Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Mammography | Research

German mammography screening program: program sensitivity between 2010 and 2016 estimated based on German health claims data

Authors: Franziska Heinze, Jonas Czwikla, Miriam Heinig, Ingo Langner, Ulrike Haug

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Program sensitivity is a key quality indicator for mammography screening programs (MSP). Estimating program sensitivity usually requires a linkage of screening and cancer registry data. For the German MSP, such data linkage-based estimates have only been reported for two out of 16 federal states. We aimed to explore the potential of estimating program sensitivity for the German MSP based on information available in health claims data.

Methods

We used data from the second-largest statutory health insurance fund in Germany, BARMER (~ 9 million members all over Germany). We included women aged 50 to 69 years with a non-initial screening mammography between 2010 and 2016 and followed them up for two years. We estimated the rate of screen-detected and interval cancers as well as program sensitivity.

Results

Per year, we included 212,400 to 303,667 women (mean age: 60–61 years). Overall, 1,992,287 non-initial MSP screening examinations conducted in these women between 2010 and 2016 were considered for the analyses. Age-standardized program sensitivity ranged between 69.9% [95% CI: 67.3–72.0%] and 71.7% [95% CI: 69.5-73.9%] during the study period. Per 1,000 non-initial screening examinations, the rate of screen-detected breast cancer ranged between 4.6 and 5.3, and the rate of interval breast cancer rates ranged between 0.6 and 0.8 for the first and between 1.3 and 1.4 for the second year after screening.

Conclusions

Our results were plausible and consistent with quality indicators estimated for the German MSP based on data linkage and thus support the value of German health claims data in this regard. The quality indicators estimated in our study are in line with levels expected according to European Guidelines.
Appendix
Available only for authorised users
Literature
1.
go back to reference Robert Koch Institut, Herausgeber und die Gesellschaft der epidemiologischen Krebsregister in Deutschland, Herausgeber. Krebs in Deutschland 2017/2018. 13. Ausgabe. Berlin; 2021. Robert Koch Institut, Herausgeber und die Gesellschaft der epidemiologischen Krebsregister in Deutschland, Herausgeber. Krebs in Deutschland 2017/2018. 13. Ausgabe. Berlin; 2021.
2.
go back to reference Perry NBM, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. 4th edition. Luxembourg; 2006. Perry NBM, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. 4th edition. Luxembourg; 2006.
3.
go back to reference Bokhof B, Khil L, Urbschat I, Gnas L, Hecht G, Heidinger O, et al. [Time trend in programme sensitivity within the german mammography screening programme in North Rhine-Westphalia and Lower Saxony]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61(12):1517–27.CrossRefPubMed Bokhof B, Khil L, Urbschat I, Gnas L, Hecht G, Heidinger O, et al. [Time trend in programme sensitivity within the german mammography screening programme in North Rhine-Westphalia and Lower Saxony]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61(12):1517–27.CrossRefPubMed
4.
go back to reference Heidinger O, Batzler WU, Krieg V, Weigel S, Biesheuvel C, Heindel W, et al. The incidence of interval cancers in the german mammography screening program: results from the population-based cancer registry in North Rhine-Westphalia. Dtsch Arztebl Int. 2012;109(46):781–7.PubMedPubMedCentral Heidinger O, Batzler WU, Krieg V, Weigel S, Biesheuvel C, Heindel W, et al. The incidence of interval cancers in the german mammography screening program: results from the population-based cancer registry in North Rhine-Westphalia. Dtsch Arztebl Int. 2012;109(46):781–7.PubMedPubMedCentral
5.
go back to reference Urbschat I, Heidinger O. [Determination of interval cancer rates in the german mammography screening program using population-based cancer registry data]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(1):68–76.CrossRefPubMed Urbschat I, Heidinger O. [Determination of interval cancer rates in the german mammography screening program using population-based cancer registry data]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(1):68–76.CrossRefPubMed
6.
go back to reference Gesetzliche Krankenversicherung. : Mitglieder, mitversicherte Angehörige und Krankenstand, Jahresdurchschnitt 2019. Bundesministerium für Gesundheit, GKV-Statistik KM1/13; 2020. Gesetzliche Krankenversicherung. : Mitglieder, mitversicherte Angehörige und Krankenstand, Jahresdurchschnitt 2019. Bundesministerium für Gesundheit, GKV-Statistik KM1/13; 2020.
7.
go back to reference Bevölkerung am Jahresende ab. 2011 (Grundlage Zensus 2011), (Primärquelle: Statistisches Bundesamt, Fortschreibung des Bevölkerungsstandes) [Internet]. [cited 17.03.2022]. Available from: www.gbe-bund.de Bevölkerung am Jahresende ab. 2011 (Grundlage Zensus 2011), (Primärquelle: Statistisches Bundesamt, Fortschreibung des Bevölkerungsstandes) [Internet]. [cited 17.03.2022]. Available from: www.​gbe-bund.​de
8.
go back to reference Programmbeschreibung. Das Mammographie-Screening-Programm in Deutschland. Berlin: Kooperationsgemeinschaft Mammographie; Februar; 2017. Programmbeschreibung. Das Mammographie-Screening-Programm in Deutschland. Berlin: Kooperationsgemeinschaft Mammographie; Februar; 2017.
9.
go back to reference Boyle P, Parkin DM. Cancer registration: principles and methods. Statistical methods for registries. IARC Sci Publ. 1991(95):126–58. Boyle P, Parkin DM. Cancer registration: principles and methods. Statistical methods for registries. IARC Sci Publ. 1991(95):126–58.
10.
go back to reference Jahresbericht Evaluation. 2012. Deutsches Mammographie-Screening-Programm. Berlin: Kooperationsgemeinschaft Mammographie; August 2015. Jahresbericht Evaluation. 2012. Deutsches Mammographie-Screening-Programm. Berlin: Kooperationsgemeinschaft Mammographie; August 2015.
11.
go back to reference Jahresbericht Evaluation 2014. Deutsches Mammographie-Screening-Program. Berlin: Kooperationsgemeinschaft Mammographie; Dezember; 2016. Jahresbericht Evaluation 2014. Deutsches Mammographie-Screening-Program. Berlin: Kooperationsgemeinschaft Mammographie; Dezember; 2016.
12.
go back to reference Jahresbericht Evaluation. 2013. Deutsches Mammographie-Screening-Programm. Berlin: Kooperationsgemeinschaft Mammographie; Juni 2016. Jahresbericht Evaluation. 2013. Deutsches Mammographie-Screening-Programm. Berlin: Kooperationsgemeinschaft Mammographie; Juni 2016.
13.
go back to reference Jahresbericht Evaluation. 2015. Deutsches Mammographie-Screening-Programm. Berlin: Kooperationsgemeinschaft Mammographie; Oktober 2017. Jahresbericht Evaluation. 2015. Deutsches Mammographie-Screening-Programm. Berlin: Kooperationsgemeinschaft Mammographie; Oktober 2017.
14.
go back to reference Evaluationsbericht. 2010. Ergebnisse des Deutschen Mammographie-Screening-Programms in Deutschland. Berlin: Kooperationsgemeinschaft Mammographie; Februar 2014. Evaluationsbericht. 2010. Ergebnisse des Deutschen Mammographie-Screening-Programms in Deutschland. Berlin: Kooperationsgemeinschaft Mammographie; Februar 2014.
15.
go back to reference Evaluationsbericht. 2011. Zusammenfassung der Ergebnisse des Mammographie-Screening-Programms in Deutschland. Berlin: Kooperationsgemeinschaft Mammographie; Dezember 2014. Evaluationsbericht. 2011. Zusammenfassung der Ergebnisse des Mammographie-Screening-Programms in Deutschland. Berlin: Kooperationsgemeinschaft Mammographie; Dezember 2014.
16.
go back to reference Jahresbericht Evaluation. 2016. Deutsches Mammographie-Screening-Programm. Berlin: Kooperationsgemeinschaft Mammographie; Oktober 2018. Jahresbericht Evaluation. 2016. Deutsches Mammographie-Screening-Programm. Berlin: Kooperationsgemeinschaft Mammographie; Oktober 2018.
18.
go back to reference Fenton JJ, Onega T, Zhu W, Balch S, Smith-Bindman R, Henderson L, et al. Validation of a Medicare Claims-based Algorithm for identifying breast cancers detected at Screening Mammography. Med Care. 2016;54(3):e15–22.CrossRefPubMedPubMedCentral Fenton JJ, Onega T, Zhu W, Balch S, Smith-Bindman R, Henderson L, et al. Validation of a Medicare Claims-based Algorithm for identifying breast cancers detected at Screening Mammography. Med Care. 2016;54(3):e15–22.CrossRefPubMedPubMedCentral
19.
go back to reference Czwikla J, Jobski K, Schink T. The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data. BMC Med Res Methodol. 2017;17(1):122.CrossRefPubMedPubMedCentral Czwikla J, Jobski K, Schink T. The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data. BMC Med Res Methodol. 2017;17(1):122.CrossRefPubMedPubMedCentral
20.
go back to reference Khil L, Heidrich J, Wellmann I, Kaab-Sanyal V, Weigel S, Heindel W, et al. Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study. BMC Cancer. 2020;20(1):174.CrossRefPubMedPubMedCentral Khil L, Heidrich J, Wellmann I, Kaab-Sanyal V, Weigel S, Heindel W, et al. Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study. BMC Cancer. 2020;20(1):174.CrossRefPubMedPubMedCentral
Metadata
Title
German mammography screening program: program sensitivity between 2010 and 2016 estimated based on German health claims data
Authors
Franziska Heinze
Jonas Czwikla
Miriam Heinig
Ingo Langner
Ulrike Haug
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11378-0

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine